PAD - Prescribing Advisory Database
Surrey
Prescribing Advisory Database

Committee Decisions

Decisions : NW Surrey Medicines Optimisation Group

Records returned : 6.

Date
Drug Profile
Narrative
Traffic Light Status
Wednesday, November 6, 2024

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

 
Red
Wednesday, November 6, 2024

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

 
Red
Wednesday, November 6, 2024

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

 
Red
Wednesday, November 6, 2024

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

 
Green
Wednesday, November 6, 2024

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

 
Blue
Wednesday, July 3, 2024

The Surrey Heartlands preferred brands of oxycodone are:

Longtec (oxycodone modified release)

Shortec (oxycodone immediate release)

The North West Surrey MOG, in agreement with ASPH, have aligned their preferred brands of oxycodone with the rest of Surrey Heartlands and now recommend Longtec / Shortec.

There is no requirement so switch patients who are currently receiving other brands.

 
Green (see narrative)